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The rapid development of new technologies for the high throughput (HT) study of proteins has increased the demand for
comprehensive plasmid clone resources that support protein expression. These clones must be full-length, sequence-verified
and in a flexible format. The generation of these resources requires automated pipelines supported by software management
systems. Although the availability of clone resources is growing, current collections are either not complete or not fully
sequence-verified. We report an automated pipeline, supported by several software applications that enabled the construction
of the first comprehensive sequence-verified plasmid clone resource for more than 96% of protein coding sequences of the
genome of F. tularensis, a highly virulent human pathogen and the causative agent of tularemia. This clone resource was
applied to a HT protein purification pipeline successfully producing recombinant proteins for 72% of the genes. These methods
and resources represent significant technological steps towards exploiting the genomic information of F. tularensis in
discovery applications.
Citation: Murthy T, Rolfs A, Hu Y, Shi Z, Raphael J, et al (2007) A Full-Genomic Sequence-Verified Protein-Coding Gene Collection for Francisella
tularensis. PLoS ONE 2(6): e577. doi:10.1371/journal.pone.0000577
INTRODUCTION
Over the past several years, complete or nearly complete sets of
clones representing the open reading frames (ORFs) of various
species have been constructed and made available [1]–[7]. These
collections often employ recombinational cloning vectors, enabling
the transfer of the ORFs into virtually any protein expression
vector in a simple conservative transfer reaction. Once transferred,
these expression clones can be employed in a wide variety of assays,
including high-throughput (HT) cell-based and proteomic discov-
ery assays [2], [4], [8]–[12] .
Clone collections have been used successfully to produce
proteins using in vitro, bacterial or insect cell expression systems
[13], [14]. Although several heterologous protein expression
systems are capable of HT protein expression, simplicity and ease
of handling have made the bacterial systems the best starting point
to express large numbers of recombinant proteins [15], [16].
Among the most important properties that transferable clone
collections should embody include comprehensive genomic
representation of the ORFs and full length sequence validation,
a combination of features that has thus far eluded the collections
available today. In part, this is because sequence validation of
clones is a tedious process that cannot be easily achieved without
a well developed automated pipeline. Nevertheless, the major use
of these collections will be to study protein function, emphasizing
the critical importance of full length sequence validation.
There is a pressing need to generate clone and protein resources
for highly infectious organisms that could be used in bioterrorism.
One such organism is Francisella tularensis, a highly virulent, gram-
negative, facultative intracellular pathogen that is the causative
agent of tularemia. F. tularensis is capable of infecting many
mammalian species and cell types, and has been isolated from
more than 250 animal species, including mammals, arthropods
and protozoa [17]. In mammalian hosts, F. tularensis thrives in the
intracellular environment of macrophages [18]. The virulent
subspecies F. tularensis tularensis is found in North America. As few
as ten cells of this subspecies are sufficient to cause an infection in
humans and 30% to 60% of untreated infections are fatal [19].
The high infection capability and transmission of the organism by
aerosols pose a significant threat, leading the U.S. Center for
Disease Control (CDC) to consider F. tularensis a category A
biodefense pathogen [19]. Recent studies on the pathogen have
focused on genomic analysis, identification of antigen targets for
vaccine development, and on understanding the mechanisms of
infection [20], [21]. The genome sequence of F. tularensis (subsp.
tularensis SCHU S4) was published in 2005 [20]. The organism has
a genome of approximately 1.9 MB that is AT rich (33% GC
content) and is predicted to encode 1,804 genes, of which 302
sequences are unique to Francisella [20]. More than 10% of genes
are predicted to be pseudogenes or gene fragments [20]. The
current annotation at NCBI includes 1,852 genes, of which 1,603
represent putative protein-coding sequences.
The study of F. tularensis pathogenesis has been hindered by the
lack of reliable genetic methods [21]. The availability of clone and
protein resources would enable functional proteomics studies
directed at the detection, prevention and treatment of this disease
agent. Comprehensive studies using recombinant proteins can be
used both to determine which proteins stimulate cell-mediated and
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and to test the proteins in the reverse vaccinology approach [22].
Using HT pipelines described here, we constructed the first
comprehensive sequence verified gene collection of F. tularensis
(subsp. tularensis SCHU S4) and a corresponding E. coli expressed
protein collection. The strategies adopted in generating these
resources, as well as some of the challenges overcome in the
completion of the collection, provide a guideline for HT gene
cloning efforts.
RESULTS
Generation of the F. tularensis gene collection
Cloning Strategy The assembly of this protein coding clone
collection was initiated by acquiring annotated genome sequence
information to predict the relevant ORFs and design the PCR
amplification primers. We started with a genome annotation
kindly provided by H. Tettelin at the Institute for Genomic
Research (TIGR) that predicted 2,036 ORFs based on a draft
genome sequence provided by H. Svenson and P. Larsson.
However, during the course of this project, a revised annotation of
the genome sequence was published [20] that reduced the number
of ORFs to 1804 with 1603 protein coding genes and adjusted
many ORF boundaries from the earlier draft. The mapping and
comparison of ORFs from preliminary and published genome
annotations can be found in Table S1. Thus, this cloning project
was accomplished in two phases corresponding to these two
annotations. The annotated ORF information was parsed and
imported into our Full-Length Expression Gene (FLEXGene)
database [2]. Relevant features stored in our database for each
ORF include CDS sequence; genome location; CDS length; GC
content; NCBI protein GI number; and FTT number (an
organism-specific identifier). Additionally, a new and unique
tracking identifier was assigned to each ORF by FLEXGene.
The cloning work-flow, shown in Figure 1, distinguishes
between two phases of clone production. All barcoded plates
and individual samples were tracked by FLEXGene, which also
stores associated results such as culture growth, colony counts and
electrophoretic gel images. In addition, each clone is associated
with its target (reference) sequence for comparison during
sequence validation.
In phase 1, all ORFs were amplified using gene specific primers
with partial att sites to generate a primary PCR product, which
was further amplified using universal primers to complete the attB
recombinational cloning sites (Figure 1). The final PCR product
was gel purified and subsequently cloned into an Entry vector,
pDONR221 (Invitrogen), to generate a master clone. New primers
were designed for all targeted ORFs in phase 2, which were
channeled into two groups. For ORFs below 2,000 bp we
employed the phase 1 strategy. For ORFs above 2,000 bp, we
omitted the second PCR reaction and instead gel purified the
amplicons with partial att sites for capture reactions using In-
Fusion
TM enzyme (Clontech) into a purified, linear pDONR221
derivative, pGW-NcoEco109. The full attB sites are regenerated as
part of the In-Fusion
TM capture step. Capture reactions were
transformed into competent bacteria and either four colonies
(phase 1) or one colony (phase 2) per gene were isolated
robotically, stored as a 15% glycerol stock, and subjected to
sequence verification.
Sequencing Strategy In all cases, sequencing began with
universally primed end reads for one isolate per gene and
proceeded to internal reads where indicated (i.e., incomplete
coverage but end reads acceptable). In cases where the first isolate
failed during sequence validation, additional isolates were tested
either by selecting another isolate (phase 1) or by re-plating the
stored transformation mix for new colonies (phase 2). In cases
where these strategies failed, cloning was repeated de novo. In both
phases, we used our Automated Clone Evaluation (ACE) software
to assemble the end reads and determine if they were sufficient to
obtain complete sequence coverage (coding plus linker sequences).
If coverage was complete, the assembled sequence was compared
with the reference sequence to determine if the clone were
acceptable. Discrepancies that occur in regions of low sequence
confidence (typically phred,25) likely reflect sequencing errors,
whereas discrepancies that occur in regions of high sequence
confidence likely reflect true differences between the clone and its
reference sequence. Clones were accepted if they had no high
confidence discrepancies leading to protein truncations or frame
shifts, no discrepancies in the critical linker regions, and no more
than two amino acid differences with the reference polypeptide. If
the coverage was not complete or if there were regions of
unacceptably low confidence sequence, additional sequencing was
performed. This process was repeated iteratively until all clones
were either accepted or rejected.
Cloning and Sequencing Results At least one isolate was
obtained for more than 99% of the targeted 2,036 ORFs in phase
1. Sequence analysis revealed that 1500 ORFs were acceptable
(73.6%; Table 1) based on the draft annotation. Subsequent to this
analysis, a revised genome sequence of F. tularensis (subsp. tularensis
SCHU S4) was published and further annotated at NCBI to predict
1,603 protein-coding genes [20]. A total of 1,104 ORFs were
identical between the two annotations, of which we had
successfully cloned 900. The other 499 ORFs were either new
or adjusted ORFs, both warranting a new cloning attempt. Thus,
the second phase focused on the 499 adjusted ORFs plus 204
ORFs that failed in the first phase (a total of 703 ORFs). Phase 2
was very successful, resulting in 696 acceptable clones for 634
ORFs (.97% for phase 2; Table 1). Overall, a total of 1,534
acceptable protein-coding clones matching the current NCBI
annotation were obtained (96% success rate relative to the
updated annotation). A complete list of these clones including
their GenBank Accession Numbers and sequences can be found in
Table S2 and at http://plasmid.hms.harvard.edu. Protein
expression clones were generated via recombinational sub-
cloning into the amino terminal hexa-histidine tag expression
vector pDEST17 (Invitrogen), using similar automated pipelines,
attaining a 97% first pass efficiency.
Automated high-throughput production of
Francisella tularensis proteins
Construction of an automated 96-well protein purification
pipeline The availability of isolated proteins for genes in F.
tularensis enables proteome scale investigation into the role that
each component of this microbe plays in cellular and humoral
immunity. We established an automated workstation for HT
production, isolation and analysis of microgram quantities of
protein, sufficient for use in immunoassays (e.g., ELISPOT).
Purification was based on immobilized metal affinity
chromatography (IMAC) using magnetic beads. Microfluidic-
based protein analysis of aliquots was performed to determine the
relative purity and quantity of the each recombinant protein.
Automated analysis via Labchip90 provided a computerized,
quantitative output of polypeptide size, concentration and purity
for each protein. In order to separate information about the
protein of interest from the other contaminating host cell proteins,
we parsed the digital output files using in-house software that
collected information about each protein peak into a tab-delimited
F. tularensis ORF collection
PLoS ONE | www.plosone.org 2 June 2007 | Issue 6 | e577Figure 1. Schematic representation of the work flow used in genome cloning of Francisella tularensis. The entire process, from design of primers
to production of clonal glycerol stocks, is shown. Most steps are common to both phases; steps specific to phase 2 are shown with a dashed line. The
process began with design of primers for each ORF in the genome (Step 1A). The primers were used to amplify ORFs from genomic DNA (Step 1B).
Subsequent amplification with universal primers (Step 1C) generated ORF sequences flanked by complete recombinational cloning sites for capture
by BP (Step 3). For amplicons captured by In-Fusion in Phase 2, universal primed PCR was not necessary (Step 2B) as the capture reaction completes
creation of the recombinational cloning sites. Successful PCR was monitored by agarose gel electrophoresis (Steps 2A and B). In Phase 1 all products
were purified from preparative gels (Step 2B) and cloned into a recombinational cloning vector via the BP clonase reaction (Steps 3), whereas in Phase
2, the capture method depended on ORF size as indicated, with only diagnostic gels needed for short amplicons (Step 2A) and preparative gels
needed when In-Fusion capture was performed. Competent bacteria were transformed with the reaction mix to yield colonies which were isolated
robotically, cultured in liquid media and stored as 15% glycerol stocks (Step 4).
doi:10.1371/journal.pone.0000577.g001
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queries to look for protein peaks of the expected molecular weight
and, if found, to obtain key parameters (size, concentration and
purity).
Expression and affinity purification of 6xHIS tagged
F. tularensis proteins
From 1961 sequence-verified full-length clones representing 96%
of protein coding F. tularensis ORFs, we successfully expressed and
purified 72% of the proteins. Protein isolation was considered
successful when at least 120 ng of the putative recombinant
protein was present and the apparent molecular weight was within
+/2 40% of the theoretical molecular weight. Representative
virtual gels of protein analysis generated from the pipeline are
shown in Figure 2 and detailed information about all successfully
purified proteins can be found in Table S3. Amongst the successful
proteins, the concentrations varied from under 200 to more than
9,000 ng/ml with an average of 1494 ng/ml (SDEV: 7425 ng/ml).
There was no apparent effect of protein size on the purification
success rate for this collection, but the overall success rate for
proteins predicted to contain trans-membrane domains (http://
www.cbs.dtu.dk/services/TMHMM/) was only 57% compared
with the overall success rate of 72%.
DISCUSSION
The genome sequence of F. tularensis was recently published and
provides a starting point to explore new avenues of research,
which should ultimately aid in the development of more effective
vaccines and foster our understanding of tularemia. In this work,
we present the production of a high quality clone collection for F.
tularensis (subsp. tularensis SCHU S4) with general utility for a broad
range of different protein-based assays. To accelerate progress
towards that goal, we developed HT protein purification pipelines
to produce proteins useful for immunological assays.
One of the major bottlenecks we encountered during the
cloning of the F. tularensis ORFeome was a significant change to
the preliminary genome annotation. We began our work using the
best available annotation and when the revised annotation of the
genome was released, we decided to incorporate this updated
information into our production pipelines. Nearly 45% of the
Table 1. Summary of the cloning process of two annotations of F. tularensis
..................................................................................................................................................
Phase1 Phase2
ORF Target 2036 703
Average ORF size (bp) 798 (range 90–4,269) 1025 (range 105–4,269)
Genome annotation TIGR preliminary annotation (Feb 2004) NCBI (Feb 2006)
Primer synthesis organization Illumina IDT
PCR polymerase KOD Phusion
Accuracy of polymerase (errors/bp) 1/290,000 1/770,000
Capture reaction BP Small gene: BP
Large gene: InFusion
Isolate picking 4 per ORF 1 per ORF
Sequencing vector pDONR221 pDONR221 & pDEST-17
PCR success rate 100% 100%
Capture success rate 99.2% 99.1%
Clones for sequence validation 2852 987
Number of reads 5835 3458
Average number of reads per clone 261.7 3.563.6
Mutation rate (errors/bp) 1/608 1/3939
Clones with linker changes 182 (6.4%) 6 (0.6%)
Clones with frameshift 239 (8.4%) 52 (5.3%)
Clones with inframe ins/del 7 (0.2%) 0
Clone with truncation mutation 84 (2.9%) 1 (0.1%)
Clone with.=3 missense 67(2.3%) 3 (0.3%)
Clone with LQ discrepancy or unassembled (not further pursued) 768 229
Number of clones accepted (includes redundant clones) 1505 696
Number of clones needed to finish a gene 1.9 1.6
Clones match perfectly with reference 626 (21.9%) 663 (95.3%)
Clone with silent only 143 (5.0%) 7 (1.0%)
Clone with,=2 mis-sense 736 (25.8%) 26 (3.7%)
Accepted ORFs matching old annotation 1500 N/A
Accepted ORFs matching current NCBI annotation 900 634
Acceptance rate (current NCBI annotation) 81.5% 90.2%
doi:10.1371/journal.pone.0000577.t001
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annotated ORFs, with the majority being partial ORFs. The new
annotation had two distinct effects on our pipeline. First, as our
clone and protein productions were carried out simultaneously,
downstream pipeline steps were burdened with some partial-
length forms of genes along with full-length forms. Second, as the
target set was revised, completion of clone production and protein
purification took longer than initially expected. Both problems
could be tolerated when balanced by an ultimately more complete
and accurate clone collection.
Other factors that affected cloning success included the source
of amplification primers and the use of polymerases with different
fidelities (see Table 1). Changing the source for gene-specific
primers in phase 2 decreased significantly the fraction of errors in
the linker region (reduced from 6% to 0.6%). In addition, using
a polymerase with higher fidelity, combined with improved primer
quality, led to a 6 fold decrease in the overall rate of mutation from
1/608 to 1/3,939 base pairs, and decreased the number of
attempted clones per final clone from 1.9 to 1.6. The second phase
did require an increased number of sequence reads per clone;
although it should be noted that this phase had an increased
number of long or challenging clones (all ORFs that had failed the
first phase were included again in the second phase).
For protein production, we relied on a widely used heterologous
bacterial expression system, optimized experimental procedures,
and developed a completely automated platform. The simplicity of
the bacterial system facilitated automation in a way that may not
have readily been possible using other protein production systems.
Moreover, we were able to use the bacterial system to produce
proteins of the required concentration and purity to perform
immuno assays for over 72% of the proteins in the F. tularensis
proteome. Failure in protein production cannot be attributed to
nonsense or other mutations in the clone set, as each clone in the
collection was fully sequenced and clones with any form of
truncation were not included in the collection. What we
categorized as ‘failure’ of the remaining 28% of the F. tularensis
proteome is attributable at least in part to yields below our cut-off
of 120 ng. Low expression may reflect inherent properties of the
proteins (such as high hydrophobic content) that could lead to
poor expression in or toxicity to the heterologous host cells.
Finally, the conditions used for HT protein expression were by
necessity optimized for a wide range of proteins. The use of
Figure 2. Representative virtual protein analysis gel of 188 proteins produced via the high-throughput protein production pipeline. The label
NTFT02#### indicates the unique identifier for each ORF of Francisella tularensis. The expected molecular weights (based on predicted protein
coding sequences of the ORFs) are shown below each lane. Black arrows (left side) indicate protein bands observed at approximately the expected
molecular weight. MW, molecular weight; NS, no sample.
doi:10.1371/journal.pone.0000577.g002
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particular proteins. The protein expression clones generated in this
study can readily be used to scale up protein expression to achieve
higher amounts of protein if required. The use of the Gateway
recombinational cloning system to build the clones further
facilitates easy shuttling of ORFs into a variety of protein
expression vectors with different affinity tags. As this collection
includes a normalized stop codon at the end of the ORF, this
collection is restricted to adding tags at only the N-terminus.
Automated protein analysis obviated the need to use gel-based
chromatography and resulted in a quantitative digital output of
protein concentration and purity. This form of output allowed
normalization of protein concentration prior to use in downstream
assays. Because our past experience suggested that HT experi-
mentation could be error prone, we took precautions at every step
to minimize manual intervention and ensure efficient tracking at
the plate and sample levels.
In summary, the first complete full length sequence verified
clone set representing the genome of F. tularensis (subsp. tularensis
SCHU S4) was created. The clone collection was successfully used
to generate a protein expression clone resource, which was
subsequently used to produce proteins for over 72% of the F.
tularensis proteome. The entire operation was automated and was
supported by a LIMS, as well as custom databases and software
tools. The clone repository serves as an important resource with
which to probe the biology of Francisella and with slight alterations,
the automated pipelines we developed will be used for a variety of
different high-throughput assays. The clones generated in this
study are openly available at http://plasmid.hms.harvard.edu. We
expect that the operational methods adopted in this study will
serve as an example for the design of similar processes relevant to
other experimental systems.
MATERIALS AND METHODS
Oligonucleotide design and ORF amplification
The ORFs were amplified using two consecutive rounds of PCR
amplification from the genomic DNA of Francisella tularensis Schu4.
In the first round, matched 59 and 39 oligonucleotides containing
gene-specific sequences with normalized start (ATG) and stop
(TAG) codons plus a short segment of the attB1 and attB2
sequences, respectively, was used to amplify each target ORF. The
resulting product was then further amplified in the second round
of PCR using ‘‘universal’’ primers that overlapped and completed
the attB1 and attB2 sequences. This two-step PCR improves fidelity
and lowers cost. Oligonucleotides were automatically designed
using in-house software employing the nearest-neighbor algorithm
to generate primer pairs that match the ends of the coding
sequences with a specified melting temperature and then appends
the partial attB tails as follows: forward primer, 59TACAAAAA-
AGCAGGCTCCACC- atgRgene-specific sequences; reverse primer,
59GTACAAGAAAGCTGGGTC -tag gene-specific sequences (under-
lining indicates partial attB sequences). Second-step PCR universal
primers were synthesized as follows: forward primer, 59-GGGGA-
CAAGTTTGTACAAAAAAGCAGGCTCC; reverse primer, 59-
GGGGACCACTTTGTACAAGAAAGCTGGGTC (underlined
are attB sequences).
For phase 1, first and second-step PCR amplifications were
done with KOD enzyme (Novagen). Conditions were as follows:
PCR-1: 0.06 mM each primer, 16 KOD buffer 1, 0.2 mM
dNTPs, 1 mM MgSO4, 16 KOD buffer 2, 200 ng genomic
DNA, 0.6U KOD polymerase; 94uC 2 min, 15 cycles [94uC1 5s ,
59uC 1 min, 68uC 6 min] 68uC 12 min, 4uC hold; PCR-2:
0.125 mM each att-primer, 16 KOD buffer1, 0.3 mM dNTPs,
1 mM MgSO4,1 6KOD buffer2, 0.6U KOD polymerase, 40%
(v/v) PCR-1; 94uC 2 min, 6 cycles [94uC1 5s ,5 9 uC 1 min, 68uC
6 min] 68uC 12 min, 4uC hold.
For phase two, both PCRs used Phusion
TM enzyme (New
England Biolabs) using the following conditions: PCR-1: 0.1 mM
each primer, 16reaction buffer, 0.2 mM dNTPs, 200 ng genomic
DNA, 0.8U Phusion polymerase, 6% (v/v) DMSO; 94uC 2 min,
15 cycles [94uC1 5s ,5 2 uC 1 min, 68uC 5 min] 68uC 12 min, 4uC
hold; PCR-2: 0.125 mM each att-primer, 1x reaction buffer,
0.2 mM dNTPs, 0.8U Phusion polymerase, 6%(v/v) DMSO, 40%
(v/v) PCR-1; 94uC 2 min, 5 cycles [94uC1 5s ,5 2 uC 1 min, 68uC
5 min] 68uC 12 min, 4uC hold.
Cloning of the F. tularensis FLEXGene collection
Cloning of the F. tularensis FLEXGene collection was performed as
described in Figure 1, and as published previously [2], [7]. Briefly,
the PCR amplified ORFs were recombined to generate ‘entry’
clones, i.e. ORFs captured in an entry or initial cloning vector that
facilitates sub-cloning of the ORFs into vectors appropriate for
specific experimental approaches. E. coli strain DH5aT1 (Invitro-
gen) was used for propagation of the clones. Expression clones for
protein production were generated from the entry clones in a one-
step recombinational sub-cloning reaction into pDEST17 (N-
terminal 6xHIS tag; Invitrogen) as described by the manufacturers
protocols and elsewhere [2]. All entry and expression recombinant
clones are stored as DNA and as bacterial glycerol stocks (15% v/v
glycerol) of single colony-selected E. coli transformants.
Protein expression
Cell growth, transformation, and protein purification were per-
formed according to the protocols in our laboratories and are
described elsewhere [14]. Briefly, BL21 star (DE3) pLysS (Invitro-
gen) transformants harboring the recombinant plasmids were
grown at 37uC as 1 ml cultures in a 96-well block (Marsh Biomedi-
cal Products) to an OD600 of ,0.7. The cultures were induced
with 1 mM IPTG and grown on a 96-well plate shaker (Multitron)
at a speed of 900 rpm. After allowing a post-induction growth for
a period of 4 hrs, the cells were harvested at 4uC and stored at
280uC for further use.
Automated 96-well protein purification
Protein purifications were performed in 96-well plates using
a BiomekFx (Beckman Coulter) robotic liquid handler under
conditions optimized in our laboratory. Cell lysis, protein binding
and washes were optimized by modulating the number of pipetting
cycles, the shaking speed and the volumes of various reagents. For
6xHIS denaturing affinity purification, the robotic deck was setup
using 15 ml of lysis buffer I (100 mM NaH2PO4, 10 mM Tris, pH
8.0), 15 ml of lysis buffer II (100 mM NaH2PO4, 10 mM Tris, 6M
Guanidine hydrochloride, 10 mM, 2-Mercaptoethanol, pH 8.0),
25 ml of wash buffer (100 mM NaH2PO4, 10 mM Tris, 8M Urea)
and 15 ml of elution buffer (wash buffer with 500 mM imidazole)
for each 96-well block. A 96-well Magnabot (Promega, #V8151)
and compatible plates (Greiner Bio-one, #650101) were used for
purification steps and the final eluate was collected in a fresh 96-
well plate.
6xHIS affinity purification
The cell pellets were thawed at room temperature for 15 min,
lysed in the presence of protease inhibitors in 100 ml lysis buffer I,
robotically resuspended in a 96-well block and agitated at 900 rpm
for 10 min (5 min in the clockwise direction and 5 min in the
counterclockwise direction). Then, 10 ml of DNase mix (10 mg/
F. tularensis ORF collection
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MnCl2) was added to the lysate followed by agitation at 900 rpm
for 10 min. Next, 100 ml of lysis buffer II was added to create
denaturing conditions. The cell lysate was allowed to bind to 30 ml
of MagneHIS (Promega #V8565) with shaking at 900 rpm for
20 min (10 min clockwise, 10 min counterclockwise). The beads
were separated using a magnabot (24-pin magnet) and the
remaining lysate was robotically pipetted and discarded. The
MagneHIS beads with bound protein were washed three times
with wash buffer. Bead adherence to the walls during washing was
prevented by shaking at 900 rpm for 2.5 min clockwise and then
2.5 min counterclockwise. The bound protein was either directly
used in assays or eluted in 50 ml elution buffer (i.e., wash buffer
with 500 mM imidazole).
Automated 96-well protein analysis
Protein analysis was performed in a 96-well format using
a capillary-based instrument, the LabChip90 (Caliper Sciences).
Protein samples were resuspended in analysis buffer (Caliper
Sciences), heated to 96uC for 5 min., cooled to room temperature
and briefly centrifuged to collect the sample. Distilled water (35 ml)
was added to each sample prior to analysis. The analysis chip
(Caliper Sciences) was primed according to the manufacturer’s
instructions. The automated protein analysis generated three
different forms of output: a chromatogram that shows migration
time; a virtual gel that mimics a Coomassie stained gel; and
a results table that includes the estimated size, quality and quantity
of each peak. The LabChip90 analyzed 96 proteins at a time with
analysis time of 40 seconds per sample. The output results were
parsed and imported into our protein database. As the error range
for the LC90 was +/2 20%, any bands corresponding to +/2
40% of expected size and above the 120 ng cutoff were annotated
as the correct band. The computed results were reviewed
manually, and in the case of small proteins (,14 kDa), the size
criteria were expanded to +/2 60% due to the resolution of the
instrument in this range.
SUPPORTING INFORMATION
Table S1 Genome annotation
Found at: doi:10.1371/journal.pone.0000577.s001 (0.19 MB
XLS)
Table S2 Complete clone list
Found at: doi:10.1371/journal.pone.0000577.s002 (1.71 MB
XLS)
Table S3 Protein expression data
Found at: doi:10.1371/journal.pone.0000577.s003 (0.17 MB
XLS)
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